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Abstract
Intracerebral hemorrhage (ICH) is a common type of fatal stroke, accounting for about 15% to 20% of all strokes.
Hemorrhagic strokes are associated with high mortality and morbidity, and increasing evidence shows that innate
immune responses and inflammatory injury play a critical role in ICH-induced neurological deficits. However, the
signaling pathways involved in ICH-induced inflammatory responses remain elusive. Toll-like receptor 4 (TLR4)
belongs to a large family of pattern recognition receptors that play a key role in innate immunity and inflammatory
responses. In this review, we summarize recent findings concerning the involvement of TLR4 signaling in ICH-
induced inflammation and brain injury. We discuss the key mechanisms associated with TLR4 signaling in ICH and
explore the potential for therapeutic intervention by targeting TLR4 signaling.
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Introduction
Intracerebral hemorrhage (ICH) is the least treatable
type of stroke and has devastating consequences [1].
Hemorrhagic strokes account for 15% to 20% of all
strokes and are associated with high mortality and mor-
bidity [2,3]. Primary damage caused by ICH occurs
within the first few hours after the onset of bleeding and
is mainly due to formation of hematomas, which com-
press adjacent tissues, thus destroying them [4]. Many
patients with ICH deteriorate progressively with no sign
of hematoma expansion, suggesting that secondary dam-
age following ICH plays a critical role in neurological
deterioration [5,6]. Several lines of evidence show that
secondary damage involves inflammation, cerebral
edema, and cellular apoptosis, ultimately leading to
blood–brain barrier disruption and massive brain cell
death [4,7-10]. The molecular mechanisms of secondary
damage after ICH have not been well-established, but
they may represent novel therapeutic targets to prevent
further brain injury.
Secondary damage following ICH is triggered by the
presence of intraparenchymal blood, which subsequently
activates cytotoxic, oxidative and inflammatory pathways
[4,10]. The toxic effects of extravasated blood result
mainly from blood components, including red blood cells
(RBCs), coagulation factors, complement components and
immunoglobulins [4,5,10]. Thrombin, a serine protease
produced rapidly after ICH onset, contributes to edema
formation and blood–brain barrier damage in early brain
injury, and activates the cytotoxic, excitotoxic and inflam-
matory pathways that are involved in secondary injury
following ICH [5,10,11]. Hemoglobin (Hb) released from
RBC lysis is a potent cytotoxic chemical that generates
free radicals and oxidative damage, causing death of
surrounding cells [5,10,12,13]. Hemin, the oxidative form
of heme, plays a critical role in Hb-induced brain injury
following ICH [5]. Hemin exerts its neurotoxic effects via
release of excessive iron, depletion of glutathione and pro-
duction of free radicals [14]. In addition, an inflammatory
response occurs after ICH, which aggravates ICH-induced
brain injury, leading to further tissue damage, blood–brain
barrier disruption and edema [4,15,16]. The inflammatory
mechanisms involved in progression of ICH-induced brain
injury include activation of microglial cells, infiltration
of inflammatory cells and production of cytokines and
chemokines. Neutrophils are believed to contribute to
brain injury after ICH [17,18]. Depletion of neutrophils
reduced blood–brain barrier disruption, axon injury and
inflammation in a rat model of ICH [18] and was found to
prevent tissue plasminogen activator (tPA)-induced ICH
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in a rat model of cerebral ischemia [17]. Neutrophils may
damage brain tissues by producing reactive oxygen spe-
cies (ROS) and releasing proinflammatory cytokines and
matrix metalloproteinases (MMPs) [19,20]. Several lines
of evidence show that activation of innate immunity and
inflammatory responses contributes to the pathogenesis
of secondary injury after ICH [4,5,10,16].
Toll-like receptors (TLRs) belong to a large family of
pattern recognition receptors that play a key role in innate
immunity and inflammatory responses [21,22]. Thirteen
mammalian TLRs have been identified in mice, eleven of
which are also found in humans. They recognize distinct
pathogen-associated molecular patterns from diverse or-
ganisms, including viruses, bacteria, mycobacteria, fungi
and parasites [23,24]. In addition, TLRs also recognize
damage-associated molecular patterns and mediate host
inflammatory responses to injury [22]. TLR1, TLR2, TLR4,
TLR5, TLR6 and TLR10 are distributed on the cell surface,
and other TLRs (TLR3, TLR7, TLR8, and TLR9) are
expressed in the intracellular endosomes [22,25]. TLR
consists of leucine-rich repeats in the extracellular ecto-
domains that bind various ligands, as well as intracellular
Toll-interleukin 1 receptor (TIR) domains that recruit
intracellular adaptor proteins, including myeloid differenti-
ation factor 88 (MyD88), TIR domain-containing adaptor-
inducing interferons (TRIFs), TIR domain-containing
adaptor protein (TIRAP) or TRIF-related adaptor molecule
(TRAM). TLR signaling pathways include at least a
MyD88-dependent pathway common to all TLRs except
TLR3, as well as a MyD88-independent pathway selective
to TLR3 and TLR4 [22,26,27]. In the MyD88-dependent
pathway, MyD88 activates signal transduction molecules,
including interleukin (IL)-1R-associated kinases (IRAKs),
tumor necrosis factor (TNF) receptor-associated factor 6
(TRAF6) and transforming growth factor (TGF)-β-activated
kinase (TAK1), ultimately leading to activation of nuclear
factorκB (NF-κB) and expression of proinflammatory cyto-
kines. In the MyD88-independent pathway, TRIF activates
signal transduction molecules including TANK-binding
kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3),
ultimately leading to expression of interferonβ (IFN-β) [26].
Our recent study shows that both the MyD88 and TRIF
signaling pathways are involved in TLR4-mediated inflam-
matory responses after ICH [28].
It has been reported that TLR4 is upregulated in a rat
model of ICH [29,30] and that its signaling pathway
contributes to poor outcome after ICH [31]. TLR4 is
activated by many endogenous ligands, such as heme
and fibrinogen [32,33], which are produced in the brain
after ICH. Our recent in vivo study shows that activa-
tion of TLR4 by heme causes ICH-induced inflamma-
tory injury via the MyD88/TRIF signaling pathway and
that effective blockade of TLR4 by its antibody sup-
presses ICH-induced inflammation [28]. Thus, the TLR4
signaling pathway could be a promising therapeutic target
for ICH treatment.
TLR4 is expressed in microglia, the resident macrophages
of the brain. Microglia are activated within minutes after
ICH [34,35] and subsequently release chemotactic factors
to recruit hematogenous phagocytes to the hemorrhagic
areas. Timely clearance of the extravasated RBCs by acti-
vated microglia/macrophages can provide protection from
local damage resulting from RBC lysis. Successful removal
of injured cells can reduce secondary damage by preven-
ting discharge of injurious proinflammatory cell contents.
Resolution of hematoma and inhibition of inflamma-
tion are considered potential targets for ICH treatment
[5,10,36,37]. In this review, we highlight the roles of
TLR signaling pathways in ICH and discuss their po-
tential as therapeutic targets.
Innate immunity and inflammation in the pathogenesis of
ICH
Microglial cells are activated within minutes after the
onset of ICH [34,35]. Activated microglial cells undergo
morphological and functional changes that include en-
largement and thickening of processes, upregulation of
proinflammatory proteins, and behavioral changes, includ-
ing proliferation, migration and phagocytosis [10,20]. The
primary neuroprotective role of activated microglia is to
clear the hematoma and damaged cell debris through
phagocytosis, providing a nurturing environment for tis-
sue recovery. However, accumulating evidence has shown
that microglial activation contributes to ICH-induced
secondary brain injury by releasing a variety of cyto-
kines, chemokines, free radicals, nitric oxide and other
potentially toxic chemicals [16,34,38,39]. In addition,
several studies have shown that inhibition of microglial
activation reduces brain damages in animal models of
ICH [39-41]. Microglial inhibitors, such as minocycline
and microglia/macrophage inhibitory factors (tuftsin
fragment 1–3), reduce ICH-induced brain injury and
improve neurological function in rodents [40-45].
Clearly, microglial activation mediates ICH-mediated
brain injury.
Besides microglia, other blood-derived inflammatory
cells, such as leukocytes and macrophages, are also ac-
tivated after ICH and contribute to ICH-induced brain in-
jury [16]. Neutrophil infiltration occurs less than 1 day
after the onset of ICH, and the infiltrating neutrophils die
by apoptosis within 2 days [35,46]. Dying leukocytes can
cause further brain injury by stimulating microglia/
macrophages to release proinflammatory factors [16].
Activated macrophages are indistinguishable from resident
microglia in morphology and function [20]. Similar to
activated microglia, activated leukocytes and macrophages
release a variety of cytokines, chemokines, free radicals and
other potentially toxic chemicals [16,20,34].
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Cytokines are well-known to be associated with in-
flammation and immune activation [47]. Although cy-
tokines are released by many cells, including microglia/
macrophages, astrocytes and neurons, the major sources
of cytokines are activated microglia/macrophages [48].
Many studies have shown that two major proinflammatory
cytokines, TNF-α and interleukin1β (IL-1β), exacerbate
ICH-induced brain injury. After ICH, TNF-α is signifi-
cantly increased both in vivo and in vitro [16,28,34,49],
which may contribute to brain edema formation and brain
injury in animal models of ICH [49,50]. Consistent with
animal studies, clinical studies support the proposition that
TNF-α contributes to ICH-induced brain injury. Plasma
TNF-α has been shown to correlate with the magnitude of
the perihematomal brain edema in patients with ICH [51].
Single-nucleotide polymorphisms in the TNF-α gene pro-
moter are associated with spontaneous deep ICH [52].
Similarly, IL-1β has been found to be upregulated after
ICH in an animal model and to produce detrimental
effects, including brain edema and blood–brain barrier dis-
ruption [28,53,54].
NF-κB, a transcription factor involved in inflammatory
responses, is also activated after ICH, leading to upre-
gulation of gene expression that contributes to brain in-
jury [34,55]. Activation of NF-κB occurs within minutes
and lasts for at least 1 week after the onset of ICH [56].
NF-κB is a key regulator of many proinflammatory cy-
tokines, such as TNF-α and IL-1β, in various pathological
conditions, including ICH [16,28,55,57]. The activity of
NF-κB correlates with perilesional cell death after ICH in
rats [58]. Activation of NF-κB is positively associated with
the progression of apoptotic cell death in patients with
ICH [59]. Therefore, understanding the signaling mecha-
nisms underlying ICH-induced NF-κB activation may fa-
cilitate identification of therapeutic targets.
Several lines of evidence have shown that NF-κB is
activated by RBCs and plasma via signaling pathways in-
volving free radicals, cytokines and glutamate receptors
[55]. It is well-known that TLR signaling pathways can
lead to NF-κB activation, resulting in production of
proinflammatory cytokines [27,60,61]. Increasing evi-
dence has shown that TLR signaling pathways play an
essential role in sterile inflammatory diseases in the cen-
tral nervous system [62-64]. Herein we review recent
advances in TLR4 signaling pathways in ICH-induced
inflammatory brain injury.
TLR4 signaling in ICH-induced inflammatory brain injury
TLRs, especially TLR4, are involved in the inflammatory
responses and neuronal damage associated with cerebral
ischemia [22,65]. Expression of TLR4 is upregulated in a
mouse model of transient cerebral ischemia [66]. In ische-
mic brain injury, TLR4-deficient mice show significant sup-
pression of inflammatory cytokine expression, including
IRF1, inducible nitric oxide synthase, cyclooxygenase2,
MMP9, and IFN-β [67]. TLR4-knockout mice have signifi-
cantly smaller infarct volumes and better neurological func-
tion than wild-type (WT) mice [66,67]. Similar to cerebral
ischemia, TLR4 expression is significantly increased after
ICH, and TLR4-knockout mice demonstrate improved
neurological function after ICH [28-31]. These animal stud-
ies agree with recent clinical findings that increased expres-
sion of TLR4 is associated with poorer functional outcome
and greater residual volume in patients with ICH [68].
However, although TLR4 participates in both cerebral
ischemia- and ICH-induced brain injuries, the signaling
pathways involved are different. Both the MyD88 and
TRIF pathways are involved in TLR4-mediated brain in-
jury in ICH [28], whereas only MyD88 is involved in is-
chemia [69]. Therefore, the roles of TLR4 in ICH and
cerebral ischemia may be different.
The roles of TLR4 in inflammation and neurological
impairment following ICH have been studied recently,
using TLR4-knockout mice, by our research group and
others [28,31]. Compared to WT mice, after ICH, TLR4-
knockout mice exhibited significantly decreased brain
water content [28] and neurological deficits [28,31]. Fur-
thermore, the perihematomal region in TLR4-knockout
mice had lower levels of infiltrating inflammatory cells,
including macrophages [28], leukocytes and monocytes
[31], as well as lower levels of inflammatory cytokines,
such as TNF-α, IL-1β and IL-6, and decreased NF-κB
activity [28]. In addition, Sansing et al. [31] reported
increased gene expression of CD36, CSF2 and CX3CL1
in TLR4-knockout mice compared to WT mice. Taken
together, these studies demonstrate that TLR4 activation
is involved in ICH-induced neurological deficits and
contributes to the detrimental inflammatory response.
TLR4 is expressed in various cell types in the central ner-
vous system, including microglia, neurons and astrocytes,
as well as in peripheral blood cells, such as leukocytes,
macrophages and platelets [22,28,30,33,70,71]. After ICH,
TLR4 mRNA and protein expression is significantly in-
creased by approximately 2 to 6 hours, peaks at day 3,
declines somewhat at day 5, but remains elevated relative
to baseline even at day 7 [28-30]. Though ICH induces
upregulation of TLR4 expression in neurons, astrocytes
and microglia, TLR4 is predominantly expressed in
CD11b-positive microglial cells in mice [28]. In addition,
TLR4 contributes to reduced recruitment of neutrophils
and monocytes in the perihematomal area after ICH in
TLR4-deficient mice [31]. Therefore, resident microglia in
the brain as well as peripheral infiltrating leukocytes and
monocytes are likely involved in the roles of TLR4 in ICH-
induced brain injury.
Microglial activation in response to ICH contributes to
ICH-induced brain injury by releasing cytokines, and inhib-
ition of microglial activation has been shown to improve
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neurological function in animal models of ICH [38-41]. Re-
cently, we investigated the role of TLR4 in microglial acti-
vation following ICH [28]. Exogenous hemin treatment of
cultured microglia increases expression of TLR4, as well as
proinflammatory cytokines, such as TNF-α, IL-1β and IL-6.
This effect is completely abolished by knockout of TLR4 or
treatment with anti-TLR4 antibodies, suggesting that TLR4
mediates hemin-stimulated microglial activation [28]. In
addition, hemin-induced expression of proinflammatory
cytokines TNF-α, IL-1β and IL-6 is completely blocked in
TLR4-knockout mice [28]. These data demonstrate that
TLR4 signaling mediates heme-induced inflammatory
injury, possibly by activating microglial cells and subse-
quently releasing proinflammatory cytokines. However,
Sansing et al. [31] reported that upregulation of IL-1β
and IL-6 genes in the perihematomal region did not sig-
nificantly differ between TLR4-knockout and WT mice,
suggesting that TLR4 signaling may not be involved in
the transcriptional regulation of proinflammatory cytokines
in perihematomal inflammation. Alternately, it may not be
possible to detect upregulation of proinflammatory cyto-
kine genes in certain cell types, such as microglia, when
the entire perihematomal region is used [31].
Using blood transfer experiments in which TLR4-
deficient blood was injected into the brains of WT mice
and WT blood into brains of TLR4-deficient mice,
Sansing et al. [31] found that TLR4 signaling within the
hemorrhage mediated the inflammatory response and
contributed to ICH-induced neurological injury. Activa-
tion of TLR4 on leukocytes or platelets within the
hemorrhage, but not on resident cells, promoted inflam-
mation and resulted in poor functional outcomes. This
study clearly demonstrated that TLR4 signaling on per-
ipheral blood cells plays a critical role in ICH-induced
brain injury.
Therefore, TLR4 signaling on resident microglia and on
blood cells within the hemorrhage is critical for ICH-
induced inflammatory injury. Because TLR4 is expressed
on resident microglia which are activated within minutes
after ICH [34,35], the TLR4 signaling on microglia probably
initiates ICH-induced inflammatory injury, causing release
of inflammatory cytokines and infiltration of neutrophils.
Significant upregulation of TLR4 expression occurs at ap-
proximately 2 to 6 hours after ICH [28-30], accompanied
by the appearance of infiltrating neutrophils in the hema-
toma (at approximately 4 hours after ICH) [46]. TLR4 sig-
naling in the neutrophils may further mediate release of
proinflammatory cytokines, which contributes to the detri-
mental inflammatory response [17,18]. There are abundant
TLR4 activators in the perihematomal region, including
heme [32], fibrinogen [33] and myeloid-related proteins 8
and 14, which are released from degranulating neutrophils
[72]. These endogenous activators can stimulate TLR4 on
leukocytes, leading to inflammatory injury.
TLR4 signaling pathways in ICH
TLRs are a group of Class I transmembrane proteins
that consist of ectodomains, transmembrane domains,
and intracellular TIR domains. TLRs recognize and bind
various ligands via leucin-rich repeats in the extracellu-
lar ectodomains. The receptor-ligand binding results in
conformational changes of the receptor, subsequently
leading to recruitment of intracellular adaptor proteins,
including MyD88, TRIF, TIRAP, or TRAM [22]. Once
recruited, these adaptors initiate downstream signaling
events, which ultimately lead to activation of transcrip-
tion factors, such as NF-κB, and subsequent expression
of various proinflammatory cytokines, such as IL-6,
TNF-α and IL-1 [22,27].
TLR4 interacts with two distinct adaptor proteins
(MyD88 and TRIF) and therefore activates two parallel
signaling pathways to initiate the activation of transcrip-
tion factors that regulate expression of proinflammatory
cytokine genes [22,26,73]. The MyD88-dependent path-
way, common to all TLRs, is essential for activation of NF-
κB and production of inflammatory cytokines [26,74]. TRIF
is essential for the TLR3- and TLR4-mediated MyD88-
independent pathway, which involves the activation of IRF-
3, leading to expression of IFN-β [26,27]. Recently, we
found that both MyD88 and TRIF signaling pathways are
involved in TLR4-mediated inflammatory responses after
ICH [28]. Deletion of MyD88 or TRIF in transgenic mice
leads to improved neurological function and reduced cyto-
kine release and macrophage infiltration following ICH.
After ICH in TLR4-knockout mice, MyD88 and TRIF ex-
pression are reduced, further demonstrating the role of
these factors in TLR4-mediated ICH sequelae. Further-
more, the ICH-induced increase in NF-κB activity is sig-
nificantly lower in TLR4-knockout mice than that in WT
mice, suggesting that TLR4 mediates ICH-induced inflam-
mation via activation of NF-κB to regulate expression of in-
flammatory cytokines.
The MyD88 pathway of TLR4 signaling activates not only
the NF-κB pathway but also the activating protein1 (AP-1)
pathway. AP-1 is a dimeric protein composed of members
of the Jun, Fos, and α-fetoprotein families of proteins [75].
AP-1 activation leads to the expression of many proin-
flammatory mediators, such as MMPs, proteases, and
cytokines such as IL-1 and IFN [76,77]. It is well-
documented that these proinflammatory mediators are
increased after ICH [16,20]. For example, MMPs, in-
cluding MMP2, MMP3, MMP9, and MMP12, have
been reported to be upregulated after ICH as a result of
their activation by proteases such as plasmin and tPA
[20,78,79]. However, the role of AP-1 in ICH has not
been explored yet. AP-1 activation in TLR4 signaling is
mainly mediated by mitogen-activated protein kinases
(MAPKs), including c-Jun N-terminal kinase (JNK),
p38 and ERK [76]. JNK, a stress-activated kinase that
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mediates apoptosis in neurons and microglia, is activated
after ICH, and inhibition of the JNK pathway results in a
significant decrease in edema and hematoma volume in
mice after ICH [80]. Therefore, proapoptotic signals may
play a role in ICH-induced inflammatory injury. However,
it remains unknown whether ILR4 can mediate ICH-
induced inflammatory injury via AP-1 activation.
Interestingly, lively and Schlichter showed that the ex-
pression of inflammatory mediators after ICH is age-
dependent [81]. They examined 27 genes, including TLR4,
and found that 18 of the 27 genes were different in expres-
sion levels or timing between young adult and aged rats
[81]. The delayed expression of TLR4 was observed in
aged rats, accompanied by a delayed and/or decreased ex-
pression of many proinflammatory cytokines such as IL-
1β and IL-6 [81]. The TLR4 signaling pathways involved
in age-related expression of proinflammatory cytokines is
not well-understood. It has been reported that lipopoly-
saccharide (LPS)-induced production of TLR4-mediated
proinflammatory cytokines is age-dependently decreased,
accompanied by a decrease in the expression of MAPKs,
but not the surface expression of TLR4 [82]. Decreased
TLR4/MPAK signaling pathway may be responsible for
age-related decrease in the production of inflammatory
cytokines.
Because the brain is a sterile organ without any path-
ogens derived from bacteria or viruses, the endogenous
molecules released after ICH become TLR stimulators.
Several endogenous molecules have been reported as
TLR4 ligands, including heme, fibrinogen, high-mobility
group protein B1 (HMGB1), heat shock proteins,
hyaluronan, oxidized low-density lipoprotein and amyl-
oid β [32,33,69,83-87]. However, the molecular mecha-
nisms underlying activation of TLR4 signaling pathways
by these different ligands are not completely understood.
Clearly, different TLR4 ligands can activate distinct sig-
naling pathways. For example, in vivo animal studies
show that heme triggers a TLR4 signaling pathway in-
volving both MyD88 and TRIF [28], whereas HMBG1
initiates only the MyD88 pathway [69], and monophos-
phoryl lipid A, a low-toxicity derivative of LPS, activates
only the TRIF pathway [88]. It remains unclear how differ-
ent TLR4 ligands selectively activate distinct signaling
pathways. However, different TLR4 receptor conformations
induced by binding of different TLR4 ligands may contrib-
ute to the pathway-specific activation [89]. The ligand-
biased signaling is well-known for G protein-coupled re-
ceptors, such as β-adrenergic receptors [25,90]. Under-
standing the mechanisms of biased signaling can provide
leads for designing more specific drugs.
Many endogenous TLR4 ligands are known to be
released during ICH. Some TLR4 ligands are crucial for
activating TLR4 to trigger ICH-induced inflammation and
inflammatory cytokine expression [28,31,91,92]. Heme,
released from RBC lysis after ICH, is essential for TLR4-
mediated inflammation because it potentiates microglial
activation and increases cytokine expression [28]. Fibrino-
gen within the clots after ICH is also critical for acti-
vation of TLR4 on platelets or leukocytes within the
hemorrhage, which contributes to poor outcome after
ICH [31]. HMGB1, known to be essential for ischemic
brain injury [65], is reported to be upregulated in the
microglia after subarachnoid hemorrhage [91], and the
HMGB1 inhibitor glycyrrhizin attenuates ICH-induced
brain injury [92]. Additional studies of the roles of en-
dogenous TLR4 ligands in ICH are warranted.
A deeper understanding of TLR4 signaling pathways
should enable development of potential therapeutic targets
for prevention and treatment of ICH. There are two ways
to block TLR signaling: direct blockade by removal of TLR
ligands (e.g., heme) and inhibition of TLRs and their down-
stream signaling pathways. Effective removal of deposited
blood and disintegrated cells by promoting hematoma
clearance has been demonstrated to reduce ICH-induced
neurological deficits in a mouse model of ICH [36,37].
Hematoma resolution could promote clearance of hemin,
thus reducing hemin-mediated activation of TLR4 and
subsequent inflammatory responses. In addition, effective
blockade of TLR4 receptor using an antibody disrupted
TLR4 signaling and has neuroprotective effects in a mouse
model of ICH [28]. Therefore, effective blockade of TLR4
signaling pathway could be a potential therapeutic strategy
for prevention and treatment of ICH.
Blockade of TLR4 signaling as a potential target in the
treatment of ICH
As TLR4 signaling plays an important role in ICH-induced
inflammatory injury, TLR4 inhibition should be beneficial.
TLR antagonists have been developed for a number of in-
flammatory and autoimmune diseases [93-95] and include
anti-TLR antibodies, small-molecule antagonists screened
from compound libraries, and antagonists derived from
medicinal plants. However, the efficacy of TLR antagonists
in ICH has not been well-studied to date.
We have found that a specific antibody (Mts50) blocked
TLR4 signaling in a mouse model of ICH [28]. TLR4 anti-
body treatment significantly reduced cerebral water content
and improved neurological function after ICH, similar to
effects observed in TLR4-knockout mice, suggesting that
blockade of the TLR4 receptor is a potential therapeutic
approach in the treatment of ICH. The neuroprotective
effects of the TLR4 antibody in ICH may be associated with
inhibition of cytokine expression and macrophage infiltra-
tion. However, the effectiveness of the antibody on hemin-
induced TLR4 activation in macrophages is controversial.
We found that the TLR4 antibody effectively suppressed
hemin-induced microglial activation in mice [28]. However,
Figueiredo et al. reported that this antibody blocked only
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LPS-induced, but not hemin-induced, TLR4 activation in
macrophages, suggesting that different TLR4 receptor con-
formations exist in response to different ligands [32]. The
discrepancy between the two studies may be due to use of
different reagents and animal models, and further studies
are needed to evaluate the efficacy of the TLR4 antibody for
ICH.
Many TLR4 antagonists have been reported to produce
anti-inflammatory effects [93-95]. Some antagonists, such
as curumin, 6-shogaol, isoliquiritigenin, and OSL07 (4-
oxo-4-(2-oxo-oxazolidin-3-yl)-but-2-enoic acid ethyl ester),
block TLR4 signaling by inhibiting homodimerization of
TLR4 [96-99]. Other agents, such as sparstolonin B,
auranofin, TAK-242, and M62812, have also been reported
to block TLR4 signaling pathways selectively [100-103].
However, most of these agents were tested in an animal
model of LPS-induced sepsis. The effects of these agents
on ICH-induced inflammation have not yet been explored.
In addition to these antagonists, many agents with mul-
tiple pharmacological mechanisms have been found to have
neuroprotective effects in animal models of ICH via inhib-
ition of TLR4 signaling. For example, oxymatrine, which
has anti-inflammatory, antioxidative, and antiapoptotic ac-
tivities, suppresses TLR4 and NF-κB gene expression and
decreases production of proinflammatory cytokines, such
as IL-6, TNF-α, and IL-1β [104]. Ginkgolide B, a specific
platelet-activating factor receptor antagonist, reduces neur-
onal cell apoptosis after traumatic brain injury in rats, pos-
sibly via inhibition of TLR4 signaling pathways [105].
Progesterone treatment inhibits TLR4 signaling pathways
and reduces brain edema and blood–brain barrier impair-
ment after subarachnoid hemorrhage in rats [106]. These
agents are not specific TLR4 receptor blockers, but they
can inhibit TLR4 signaling to reduce ICH-induced inflam-
matory injury.
Paradoxically, TLR4 activation with low doses of LPS
prior to ischemic brain injury protects against subse-
quent severe ischemic injury [107-109]. The mechanisms
of preconditioning by TLR4 activation in ischemic brain
injury are not fully understood. Recent studies have
shown that LPS preconditioning redirects TLR4 singling
through the TRIF-IRF3 pathway, but not through the
MyD88 pathway [109,110]. Enhanced IRF3 activity and
increased anti-inflammatory IFN gene expression con-
tribute to the beneficial effects of LPS preconditioning
[109]. Though the suppression of NF-κB activity is sup-
pressed in LPS preconditioning mice following ischemic
injury, proinflammatory cytokine production does not
change, suggesting that besides the TLR4 signaling path-
way, other signaling cascades and transcription factors
are involved in proinflammatory cytokine production
during ischemic injury [109]. However, there have been
relatively few studies examining the effects of precon-
ditioning by TLR4 activation on ICH. It remains to be
determined whether the TRIF/IRF3 pathway and enhanced
anti-inflammatory IFN production are preferentially in-
volved in preconditioning by TLR4 activation in ICH. It
has been reported that progesterone inhibits TLR4/NF-κB
signaling pathway and decrease proinflammatory cytokine
production in rats following subarachnoid hemorrhage
[106], suggesting that suppressed proinflammatory signal-
ing may contribute to preconditioning by TLR4 activation
in ICH. Therefore, suppressed proinflammatory signal-
ing and/or enhanced anti-inflammatory IFN signaling
may be associated with preconditioning by TLR4 activa-
tion in ICH. Additional studies of the mechanisms of
preconditioning by TLR4 activation in ICH are warranted.
Heme removal and hematoma resolution as potential
targets in the treatment of ICH
RBC lysis occurs at approximately 24 hours after the onset
of ICH and continues for the next several days, leading
to release of cytotoxic hemoglobin [111]. Hemoglobin
then degrades to hemin, the oxidative form of heme [14].
Hemin is gradually cleared by hematogenous phagocytes
and resident microglia [10]. Once inside these cells, hemin
is degraded by heme oxygenase (HO) into biliverdin and
carbon monoxide, releasing cytotoxic iron. The toxic ef-
fects of hemoglobin/hemin include release of redox-active
iron, depletion of glutathione, and production of free ra-
dicals [14]. To avoid the toxicity of hemoglobin/hemin,
these substances are cleared from the extracellular space
via binding to haptoglobin and hemopexin or via phago-
cytosis by microglia/macrophages.
Haptoglobin, an abundant protein in blood plasma, has
the ability to bind hemoglobin. In the brain, it is produced
and released by oligodendrocytes, thereby protecting the
brain against extravascular hemoglobin toxicity [112]. Ex-
pression of haptoglobin is increased around the hematoma
in animal models of ICH. Haptoglobin-deficient mice are
more vulnerable to ICH-induced brain injury, and mice
with haptoglobin overexpression are less susceptible to in-
jury [112]. Sulforaphane, an NF-E2-related factor2 (Nrf2)
activator, increases haptoglobin in the brain and reduces
brain injury following ICH [112]. In addition, sulforaphane
treatment increases expression of Nrf2-mediated antioxi-
dant genes, such as catalase, superoxide dismutase, and
glutathioneS-transferase, in the brain after ICH [113]. The
antioxidative effects of sulforphane are correlated with
reduction of brain damage, measured by brain edema,
blood–brain barrier impairment, cortical apoptosis, and
motor deficits [114].
Peroxisome proliferator-activated receptorγ (PPARγ)
plays an important role in augmenting phagocytosis and
promoting hematoma absorption [36,37]. PPARγ is a
ligand-dependent transcription factor that regulates the
expression of several target genes, such as scavenger re-
ceptor CD36 [36,37]. CD36, a class B scavenger receptor,
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is important for phagocytic activity [115,116]. Treatment
with PPARγ agonists, such as rosiglitazone and 15d-PGJ2,
increases expression of CD36 and promotes phagocytosis
of RBCs by microglia/phagocytes in both in vitro and
in vivo models of ICH [36,37], and anti-CD36 antibodies
prevent PPARγ agonist-induced increases in phagocytosis
[37]. In addition, in an animal model, treatment of ICH
with PPARγ agonists accelerated hematoma resolution
and reduced neurological deficits [36,37].
ROS are produced after ICH and contribute to ICH
pathogenesis [4,5,13,34]. In addition, phagocytosis gene-
rates a large amount of ROS that can damage macro-
phages and neurons. PPARγ also plays an important role
in protecting microglia/macrophages from oxidative dam-
age via upregulation of the antioxidant catalase [36,37].
PPARγ agonists upregulate catalase expression in micro-
glia in vitro and in vivo after ICH, enhance phagocytosis
in vitro and increase hematoma absorption in vivo [37].
The PPARγ-mediated upregulation of catalase reduces oxi-
dative stress, as demonstrated by a significant reduction of
extracellular hydrogen peroxide in cultured microglia [37].
Phagocytosis of RBCs by microglia is also enhanced by
upregulation of catalane, as demonstrated by the finding
that addition of exogenous catalane to the culture media
promotes phagocytosis [37].
PPARγ can also induce neuroprotection after ICH via
anti-inflammatory effects. In both in vitro and in vivo
experiments, PPARγ activators reduced expression of pro-
inflammatory genes, including TNF-α, IL-1β,MMP9, and
inducible nitric oxide synthase [37]. PPARγ is known to
inhibit DNA binding of NF-κB [34,55], which controls
expression of proinflammatory cytokines and enzymes,
suggesting that the anti-inflammatory effect of PPARγ
probably results from inhibition of NF-κB [37,117].
TLR4 signaling in hematoma resolution
Microglia/macrophages express the scavenger receptor
CD36, which has been reported to assist in phagocytosis-
mediated removal of RBCs after ICH [37]. PPARγ agonists
can promote phagocytosis of RBCs by microglia/phagocytes
through upregulation of CD36 [36,37]. In addition, PPARγ
agonists suppress the subarachnoid hemorrhage-induced
inflammatory response by inhibiting TLR4 signaling [118].
Knockout of TLR4 results in upregulation of CD36 in
the perihematomal region [31], suggesting that the TLR4
signaling pathway could play a role in hematoma reso-
lution. In agreement with this hypothesis, we found that
hematoma resolved significantly faster in TLR4-knockout
mice than in WT mice, as shown in Figure 1. Specifically,
hematoma started to resolve at 3 days after ICH and almost
completely resolved by 5 days. These data demonstrate that
the TLR4 signaling pathway is involved in hematoma reso-
lution after ICH, and the underlying mechanisms are cur-
rently under investigation.
Conclusions and perspectives
Increasing evidence has shown that TLR4 signaling plays
important roles in ICH-induced inflammatory brain injury
by stimulating activation of microglial cells, infiltration of
leukocytes, and production of cytokines and chemokines
[28,31]. The TLR4 signaling pathway involved in ICH-
induced inflammatory injury includes ligands (e.g., heme),
TLR4 itself, and its downstream pathways, including
adaptor proteins (MyD88 and TRIF) and transcription
factors, such as NF-κB [28]. Therefore, TLR4 and its sig-
naling pathways are potential targets for developing effect-
ive medical treatment of ICH.
There are many challenges to be overcome before inhib-
ition of TLR4 signaling can be used in the prevention and
treatment of ICH. Though inhibition of TLR4 signaling by
anti-TLR4 antibodies or deletion of TLR4 genes can ef-
fectively reduce ICH-induced neurological deficits in mice
[28], specific TLR4 antagonists that inhibit TLR4 signaling
have not been investigated in models of ICH. In addition,
a diverse range of endogenous ligands may activate TLR4
signaling to trigger the inflammatory response that is crit-
ical in ICH-induced brain injury. However, it remains un-
clear how these ligands activate TLR4 signaling, which
ligands are the most critical, how TLR4 receptors recruit
adaptor proteins and activate transcription factors, and
whether TLR4 signaling pathways are similar across cell
types (e.g., microglia versus leukocytes). Whether TLR4
interacts with other TLRs in ICH-induced inflammatory
injury requires further investigation. Better understanding
Figure 1 TLR4 knockout results in faster hematoma resolution.
(A) Representative brain sections from WT and TLR4-knockout mice
at 1, 3, and 5 days after intrastriatal injection of blood. (B) Compared
with WT mice, TLR4-knockout mice had significantly smaller
hemotomas at 3 and 5 days after ICH. Hematoma volume was
measured on coronal slices (2 mm thick) using image analysis
software. Scale bar: 1 mm. **P < 0.05 versus WT mice.
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of the roles of TLR4 signaling in ICH will facilitate devel-
opment of ICH treatments.
Brain injury following ICH is triggered by the presence of
intraparenchymal blood. The mechanisms of ICH-induced
brain injury are numerous, including cytotoxic, oxidative,
and inflammatory pathways. It would be beneficial to de-
velop a medical treatment that promotes hematoma reso-
lution and inhibits cytotoxic, oxidative, and inflammatory
insults following ICH. For example, PPARγ activators re-
duce ICH-induced brain injury by improving hematoma
resolution and reducing oxidative injury [36,37]. Another
promising intervention is inhibition of TLR4 signaling,
which also promotes hematoma resolution (see Figure 1)
and inhibits ICH-induced inflammation [28]. However, the
molecular mechanisms underlying hematoma resolution
and cytotoxic, oxidative, and inflammatory injury following
ICH remain elusive. Further research into the complex
mechanisms involved in ICH pathogenesis will facilitate
identification of novel therapeutic targets.
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